Fulgent Genetics, Inc. Common Stock FLGT
i
Market dataready · fetched 2026-11-04T00:53:28.214Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:00:09.918872483Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-04T00:53:27.721252+00:00
Fulgent Genetics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 15.13 | 176.9% | 27.0% | |||
| 25Δ | 22.16 | 78.7% | 16.8% | 16.23 | 157.4% | 22.1% |
| 30Δ | 21.65 | 78.6% | 14.9% | 17.33 | 137.8% | 17.1% |
| 35Δ | 21.14 | 78.6% | 13.0% | 17.96 | 124.3% | 14.3% |
| 40Δ | 20.63 | 78.5% | 11.1% | 18.50 | 111.8% | 11.9% |
| 45Δ | 20.13 | 78.4% | 9.2% | 19.04 | 99.4% | 9.5% |
| 50Δ | 19.65 | 80.8% | 8.0% | 19.58 | 86.9% | 7.0% |
| 55Δ | 19.17 | 84.1% | 7.1% | 20.10 | 77.1% | 5.0% |
| 60Δ | 18.70 | 87.4% | 6.3% | 20.58 | 76.4% | 4.3% |
| 65Δ | 18.23 | 90.6% | 5.4% | 21.05 | 75.6% | 3.6% |
| 70Δ | 17.76 | 93.9% | 4.5% | 21.52 | 74.9% | 2.9% |
| 75Δ | 17.05 | 101.6% | 3.8% | 21.99 | 74.2% | 2.2% |
| 80Δ | 16.09 | 114.5% | 3.2% | 22.46 | 73.4% | 1.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.13
- IV
- 176.9%
- B/E move
- 27.0%
25Δ
- Pseudo strike
- 22.16
- IV
- 78.7%
- B/E move
- 16.8%
- Pseudo strike
- 16.23
- IV
- 157.4%
- B/E move
- 22.1%
30Δ
- Pseudo strike
- 21.65
- IV
- 78.6%
- B/E move
- 14.9%
- Pseudo strike
- 17.33
- IV
- 137.8%
- B/E move
- 17.1%
35Δ
- Pseudo strike
- 21.14
- IV
- 78.6%
- B/E move
- 13.0%
- Pseudo strike
- 17.96
- IV
- 124.3%
- B/E move
- 14.3%
40Δ
- Pseudo strike
- 20.63
- IV
- 78.5%
- B/E move
- 11.1%
- Pseudo strike
- 18.50
- IV
- 111.8%
- B/E move
- 11.9%
45Δ
- Pseudo strike
- 20.13
- IV
- 78.4%
- B/E move
- 9.2%
- Pseudo strike
- 19.04
- IV
- 99.4%
- B/E move
- 9.5%
50Δ
- Pseudo strike
- 19.65
- IV
- 80.8%
- B/E move
- 8.0%
- Pseudo strike
- 19.58
- IV
- 86.9%
- B/E move
- 7.0%
55Δ
- Pseudo strike
- 19.17
- IV
- 84.1%
- B/E move
- 7.1%
- Pseudo strike
- 20.10
- IV
- 77.1%
- B/E move
- 5.0%
60Δ
- Pseudo strike
- 18.70
- IV
- 87.4%
- B/E move
- 6.3%
- Pseudo strike
- 20.58
- IV
- 76.4%
- B/E move
- 4.3%
65Δ
- Pseudo strike
- 18.23
- IV
- 90.6%
- B/E move
- 5.4%
- Pseudo strike
- 21.05
- IV
- 75.6%
- B/E move
- 3.6%
70Δ
- Pseudo strike
- 17.76
- IV
- 93.9%
- B/E move
- 4.5%
- Pseudo strike
- 21.52
- IV
- 74.9%
- B/E move
- 2.9%
75Δ
- Pseudo strike
- 17.05
- IV
- 101.6%
- B/E move
- 3.8%
- Pseudo strike
- 21.99
- IV
- 74.2%
- B/E move
- 2.2%
80Δ
- Pseudo strike
- 16.09
- IV
- 114.5%
- B/E move
- 3.2%
- Pseudo strike
- 22.46
- IV
- 73.4%
- B/E move
- 1.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 65.13% | |
| 52.57% | |
| 57.71% | |
| 58.43% | |
| 57.74% | |
| 53.49% | |
| 57.64% | |
| 54.69% | |
| 47.65% | |
| 56.04% | |
| 56.77% | |
| 48.50% | |
| 53.68% | |
| 95.10% | |
| 54.82% | |
| 54.73% | |
| 52.19% | |
| 59.13% | |
| 57.51% | |
| 62.72% | |
| 65.47% | |
| 66.00% | |
| 58.11% | |
| 63.38% | |
| 69.33% | |
| 69.31% | |
| 71.62% | |
| 67.71% | |
| 59.53% | |
| 65.33% | |
| 64.15% |
Diagnostics & Research
GH
Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood…
More →GRAL
GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection…
More →ICLR
ICON Public Limited Company, a clinical research organization, provides outsourced marketing and development services in Ireland, the rest of Europe, the United States and…
More →IDXX
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal…
More →ILMN
Description unavailable
More →IMDX
OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.
More →